glp 1 research Perspectives in GLP-1 Research: New Targets, New Receptors: Trends in Endocrinology & Metabolism Current Insights, Advantages and Challenges
Description
Novo Nordisk A/S: CagriSema Demonstrated Superior HbA1c Reduction of 1.91 Percent Points and Weight Loss of 14.2 Percent in Adults with Type 2 Diabetes in the REIMAGINE 2 Trial
doi: 10.3390/biom15050622, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 77
Inflammation in neurodegenerative diseases
Not with the right approach
Feng, P., Yu, Dm., Chen, Lm
Since the development of the first GLP-1 medication, Byetta, by Amylin Pharmaceuticals in 2005 and its commercialization by AstraZeneca, these drugs have been widely used for managing type 2 diabetes
